Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled trial of Symbioflor 2 in IBS-D
2018-004626-28Phase 4Active
- Sponsor
- Symbiopharm
- Start
- Apr 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Symbioflor 2 with Placebo (2 arms). Primary endpoint: Combined primary endpoint: Bristol Stool Scale and Abdominal Pain Intensity. Started Apr 2019; status: active.
02
Drugs
Escherichia coli Symbio DSM 17252
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2018-004626-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004626-28.